CTAS vs EBS
Cintas Corporation (CTAS) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. EBS currently screens at market cap $416.4M.
Not investment advice. Open the CTAS and EBS stock pages for the full models.
Not investment advice.